New dimensions in cardiovascular risk: exploring the latest cardiovascular outcomes trials in type 2 diabetes

3 September 2019 (16:00 - 16:05)

Organised by:

Video

Sign in for access options

Slides

About the speaker

Doctor Mikhail Kosiborod

St. Luke's Mid America Heart Institute, Kansas City (United States of America)

3 More presentations in this session

Presentation thumbnail

Analysing the advantages of glucagon-like peptide-1 receptor agonists/sodium-glucose cotransporter 2 inhibitors in high vs. low cardiovascular disease risk

Professor J. Deanfield (London, GB)

Presentation thumbnail

Exploring the future role of glucagon-like peptide-1 receptor agonists in cardiovascular disease risk reduction

Doctor B. Scirica (Boston, US)

Presentation thumbnail

Connecting with the speakers: Questions and Answers

Doctor M. Kosiborod (Kansas City, US) Professor J. Deanfield (London, GB) Doctor B. Scirica (Boston, US)

Access the full session

Session thumbnail

Experts on the spot: exploring new dimensions in glucagon-like peptide-1 receptor agonists and cardiovascular risk

The Event

ESC Congress 2019

3 September 2019 16:00 CET

You may be interested in

Congress Presentation

Effects of once-weekly semaglutide on coronary outcomes in patients with type 2 diabetes mellitus with or at high risk for cardiovascular disease: insights from the SUSTAIN-6 trial

7 April 2022

Webinar

EAPC Webinar: Type 2 Diabetes and cardiovascular risk

12 March 2019

Congress Session

Hypertension with cardiometabolic comorbidities: which drugs to select and which to avoid

30 August 2025

Congress Presentation

Association of kidney and cardiovascular outcomes in patients with type 2 diabetes mellitus: insights from the EMPA-REG OUTCOME trial

29 June 2021

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources